Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Uterine Cervical Neoplasms × defactinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 7 Ovarian Neoplasms 4 Mesothelioma, Malignant 4 Carcinoma, Non-Small-Cell Lung 3 Neoplasms 2 Mesothelioma 2 Lung Neoplasms 2 Glioblastoma 2 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Phase IB 1 Neoplasms, Mesothelial 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Melanoma 1 Low-Grade Serous Ovarian Cancer 1 Low Grade Serous Ovarian Cancer 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Endometrioid 1 Brain Neoplasms 1 Advanced Colorectal Cancer 1 Adenoma 1 Adenocarcinoma of Lung 1

Interventions

Cisplatin 139 Radiotherapy 62 Paclitaxel 60 Brachytherapy 58 Carboplatin 56 pembrolizumab 52 Bevacizumab 33 Gemcitabine 26 Topotecan 22 Radiation 22 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 20 Colposcopy 20 Nivolumab 18 human papillomavirus vaccine, L1 type 16, 18 17 Papillomavirus Vaccines 17 Platinum 15 Magnetic Resonance Spectroscopy 15 Drug Therapy 15 Cyclophosphamide 15 Docetaxel 14 Biopsy 14 atezolizumab 13 Radiotherapy, Intensity-Modulated 13 fludarabine 12 Taxes 12 Methods 11 Ipilimumab 11 Early Intervention, Educational 11 1,2-diaminocyclohexaneplatinum II citrate 11 toripalimab 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05512208 2025-10-22

DURAFAK

University of Oklahoma

Phase 2 Recruiting

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡